AIM ImmunoTech expands patent portfolio with new Netherlands patent

AIM ImmunoTech (AIM) announced that the Netherlands Patent Office has granted Patent No. 2,032,813 – a compositions and methods patent – covering Ampligen for use in the treatment of the post-COVID condition of fatigue. The patent inventors, AIM CEO Thomas Equels and AIM Medical Officer David R. Strayer, M.D., have assigned the granted patent to the Company. AIM CEO Thomas K. Equels commented, “Over the course of the past year in particular, we have had great success in expanding our global intellectual property portfolio, with U.S. patents for the combination of Ampligen with immune checkpoint inhibitors for the treatment of challenging cancers, for a novel method for the treatment of Chronic Fatigue Syndrome, and for methods and compositions for treating debilitating endometriosis. We are pleased to continue executing on that initiative and to further broaden AIM’s existing portfolio for the treatment of COVID-19-related illnesses with this new Netherlands patent. Much of our European research is conducted in the Netherlands at the world-renowned Erasmus Medical Center.”